By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


MaxCyte, Inc. 

22 Firstfield Road
Suite 250
Gaithersburg  Maryland  20878  U.S.A.
Phone: 301-944-1700 Fax: 301-944-1703



Company News
MaxCyte Appoints Executive Vice President Of Global Marketing 8/14/2017 6:55:35 AM
MaxCyte And NIAID To Collaborate On Research For Ultra-Rare Disease Therapy 6/6/2017 8:17:42 AM
CRISPR (CRSP) And Casebia Therapeutics Announce Commercial License Agreement With MaxCyte, Inc. 3/14/2017 8:09:05 AM
MaxCyte, Inc. Release: Biopharma Trading Update 1/24/2017 10:25:49 AM
MaxCyte, Inc. Release: Company, NIH NIAID Study Published In Science Translational Medicine Demonstrates CRISPR-Cas9 Repair Of X-Linked Chronic Granulomatous Disease (CGD) Gene 1/12/2017 7:31:14 AM
MaxCyte, Inc. Announces Strategic Immuno-Oncology Collaboration To Advance New Generation Of CAR-Based Cell Therapies 12/21/2016 7:48:47 AM
MaxCyte, Inc. Appoints Executive Vice President, Business And Strategic Development 11/2/2016 7:25:21 AM
MaxCyte, Inc. Announces A CRADA With US Army Medical Research Institute Of Infectious Diseases For An Exploratory Research Collaboration On Rapid Response Medical Countermeasures 5/17/2016 10:27:34 AM
MaxCyte, Inc. To Present Gene Editing Results At The American Society Of Gene And Cell Therapy Annual Meeting 4/21/2016 2:17:02 PM
MaxCyte, Inc. To Present Data On Expression And Functionality Of Bispecific Antibodies Produced Via Transient Transfection 3/10/2016 2:01:59 PM